Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms.

Literature DB >> 29051283

Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms.

Gabriela S Hobbs¹, Amritha Varshini Hanasoge Somasundara², Maria Kleppe², Rivka Litvin³, Maria Arcila⁴, Jihae Ahn⁵, Anna Sophia McKenney^2,6, Kristina Knapp⁷, Ryan Ptashkin⁴, Howard Weinstein⁸, Murk-Hein Heinemann⁹, Jasmine Francis⁹, Suzanne Chanel³, Ellin Berman³, Michael Mauro³, Martin S Tallman³, Mark L Heaney¹⁰, Ross L Levine^2,3, Raajit K Rampal¹¹.

Abstract

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2017 PMID： 29051283 PMCID： PMC5777196 DOI： 10.3324/haematol.2017.177600

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

14 in total

1. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome.

Authors: W G An; T W Schulte; L M Neckers
Journal: Cell Growth Differ Date: 2000-07

2. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

Authors: Giovanni Barosi; Gunnar Birgegard; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Jean-Jacques Kiladjian; Eva Lengfelder; Mary Frances McMullin; Francesco Passamonti; John T Reilly; Alessandro M Vannucchi; Tiziano Barbui
Journal: Blood Date: 2009-03-10 Impact factor: 22.113

3. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors: Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal: N Engl J Med Date: 2012-03-01 Impact factor: 91.245

4. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors: Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal: N Engl J Med Date: 2010-09-16 Impact factor: 91.245

5. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.

Authors: Warren Fiskus; Srdan Verstovsek; Taghi Manshouri; Rekha Rao; Ramesh Balusu; Sreedhar Venkannagari; Nalabothula Narasimha Rao; Kyungsoo Ha; Jacqueline E Smith; Stacey L Hembruff; Sunil Abhyankar; Joseph McGuirk; Kapil N Bhalla
Journal: Clin Cancer Res Date: 2011-10-05 Impact factor: 12.531

6. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.

Authors: Maria Kleppe; Minsuk Kwak; Priya Koppikar; Markus Riester; Matthew Keller; Lennart Bastian; Todd Hricik; Neha Bhagwat; Anna Sophia McKenney; Efthymia Papalexi; Omar Abdel-Wahab; Raajit Rampal; Sachie Marubayashi; Jonathan J Chen; Vincent Romanet; Jordan S Fridman; Jacqueline Bromberg; Julie Teruya-Feldstein; Masato Murakami; Thomas Radimerski; Franziska Michor; Rong Fan; Ross L Levine
Journal: Cancer Discov Date: 2015-01-08 Impact factor: 39.397

7. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors: Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal: Blood Date: 2008-11-06 Impact factor: 22.113

8. Detection of mutations in myeloid malignancies through paired-sample analysis of microdroplet-PCR deep sequencing data.

Authors: Donavan T Cheng; Janice Cheng; Talia N Mitchell; Aijazuddin Syed; Ahmet Zehir; Nana Yaa T Mensah; Alifya Oultache; Khedoudja Nafa; Ross L Levine; Maria E Arcila; Michael F Berger; Cyrus V Hedvat
Journal: J Mol Diagn Date: 2014-07-10 Impact factor: 5.568

9. First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors.

Authors: Cristiana Sessa; Geoffrey I Shapiro; Kapil N Bhalla; Carolyn Britten; Karen S Jacks; Monica Mita; Vali Papadimitrakopoulou; Tim Pluard; Thomas A Samuel; Mikhail Akimov; Cornelia Quadt; Cristina Fernandez-Ibarra; Hong Lu; Stuart Bailey; Sandra Chica; Udai Banerji
Journal: Clin Cancer Res Date: 2013-06-11 Impact factor: 12.531

10. Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors.

Authors: Toshihiko Doi; Yusuke Onozawa; Nozomu Fuse; Takayuki Yoshino; Kentaro Yamazaki; Junichiro Watanabe; Mikhail Akimov; Matthew Robson; Narikazu Boku; Atsushi Ohtsu
Journal: Cancer Chemother Pharmacol Date: 2014-07-25 Impact factor: 3.333

11 in total

Review 1. New Concepts of Treatment for Patients with Myelofibrosis.

Authors: Prithviraj Bose; Mansour Alfayez; Srdan Verstovsek
Journal: Curr Treat Options Oncol Date: 2019-01-24

2. ACY-1215 suppresses the proliferation and induces apoptosis of chronic myeloid leukemia cells via the ROS/PTEN/Akt pathway.

Authors: Yuefeng Qin; Yang Liang; Guoyun Jiang; Yuhang Peng; Wenli Feng
Journal: Cell Stress Chaperones Date: 2022-06-08 Impact factor: 3.827

3. Heat shock protein 90 is a new potential target of anti-rejection therapy in allotransplantation.

Authors: Takeshi Maehana; Toshiaki Tanaka; Kohei Hashimoto; Ko Kobayashi; Hiroshi Kitamura; Naoya Masumori
Journal: Cell Stress Chaperones Date: 2022-04-09 Impact factor: 3.827

Review 4. Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.

Authors: Yammy Yung; Emily Lee; Hiu-Tung Chu; Pui-Kwan Yip; Harinder Gill
Journal: Int J Mol Sci Date: 2021-01-11 Impact factor: 5.923

Review 5. Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications.

Authors: David M Ross; Jeffrey J Babon; Denis Tvorogov; Daniel Thomas
Journal: Haematologica Date: 2021-05-01 Impact factor: 9.941

6. HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias.

Authors: Rony Mshaik; John Simonet; Aleksandra Georgievski; Layla Jamal; Shaliha Bechoua; Paola Ballerini; Pierre-Simon Bellaye; Zandile Mlamla; Jean-Paul Pais de Barros; Audrey Geissler; Pierre-Jean Francin; François Girodon; Carmen Garrido; Ronan Quéré
Journal: Blood Cancer J Date: 2021-03-18 Impact factor: 11.037